ribociclib,fulvestrant
novartis
['mbc', 'ribociclib', 'breast']
#asco22 | june 4 | oral abstract session | breast cancer
phase ii trial of fulvestrant or exemestane with or w/o ribociclib after progression on anti-estrogen tx + cdk 4/6i in pts w/unresectable or hr+ her2-neg mbc
presenter: kevin kalinsky, md, ms 
As Georgia's NCI Comprehensive Cancer Center, we are at the forefront of cancer research, innovation, and discovery. Request patient appointment: (888) 946-7447